ASAnne L. R. Schuster

Anne L. R. Schuster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anne L. R. Schuster has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Community priorities for programs using HIV molecular epidemiology: A best-worst scaling

    by Anne Lr Schuster, Juli Bollinger, Travis Sanchez, Jeremy Sugarman, John Fp Bridges

    Background: HIV molecular epidemiology (HIV-ME) uses genetic sequencing to study viral evolution, detect transmission clusters, and guide public health responses. Ethical, legal, and social implications of HIV-ME have been raised, yet quantitative evidence on community perspectives remains limited. We quantified community priorities for HIV-ME program features and examined their heterogeneity. Methods: Adult cisgender men who have sex with men, including people living with HIV (PLWH), were recruited from the 2023-2024 American Men’s Internet Survey. Best-worst scaling assessed the importance of 11 HIV-ME features across 11 choice tasks using a Youden experimental design. Aggregate results were estimated using conditional logit models and rescaled to importance scores summing to 100%. Heterogeneity in priorities was assessed using stratified models and latent class analysis. Results: Among 747 people who completed the survey, 18% were PLWH, 35% were under 40, 34% reported concern about stigma, and 38% resided in states with active HIV criminalization statutes. “Ensuring privacy” was the most important feature, followed by HIV-ME uses for cluster detection and response, studying viral evolution, and evaluating prevention. Priorities did not differ when stratified by HIV status (p<0.01). Two latent classes emerged: a larger “Use the Data” group (n=472, 63%) placed 64% of importance on HIV-ME uses, and a smaller ‘Protect the Data’ group (n=275, 37%) placed 26% of importance on HIV-ME uses and 64% on: ensuring privacy, obtaining permission for and providing disclosure about data use, and limiting law-enforcement access. Conclusions: Community support is broad for HIV-ME uses, particularly with protections for data privacy, access, and use.

  • Open Access

    From framework to practice: applying the proteus-practice framework to learn lessons for integrating PROs in clinical care

    by Anne L R Schuster, Claire Snyder, Lotte Haverman, Jennifer R Cracchiolo, Liv Marit Valen Schougaard, Amy M Cizik, Alex Tarlochan Singh Sandhu, Michael Brundage, Norah L Crossnohere

    Purpose: As the use of patient-reported outcomes (PROs) in clinical practice expands, there is a growing need to understand how PROs are being integrated across diverse healthcare settings. We aimed to use the PROTEUS-Practice Framework to systematically describe real-world approaches to PRO integration into clinical care and identify lessons learned. Methods: Participants in the international PROTEUS Consortium were invited to submit case studies describing PRO applications in clinical care. Contributors completed a structured template aligned with the PROTEUS-Practice Framework, which outlines 16 steps for PRO integration across design, implementation, and management stages. Case studies were descriptively summarized by framework step and responses were thematically analyzed by framework stage to identify lessons learned. Results: Five case studies described the integration of PROs in diverse clinical contexts, including three within individual health systems and two spanning multiple health systems. Fifteen cross-cutting lessons learned emerged across the PROTEUS-Practice Framework stages. Themes identified in at least three case studies include the importance of stakeholder training during design, PRO champions during implementation, and EHR integration to support management. Clear goals, alignment of expected outcomes, iterative design processes, user-friendly visualizations, and regular system updates were also commonly emphasized as critical to successful integration. Conclusion: The PROTEUS-Practice Framework provided a structured approach for describing real-world approaches to PRO integration in clinical care. Its use enabled the identification of cross-cutting lessons learned that offer practical guidance for optimizing PRO integration and tailoring its use in diverse clinical contexts.

  • Open Access

    More evidence is needed to improve molecular HIV surveillance for cluster detection and response

    by Anne Lr Schuster, Juli Bollinger, Gail Geller, Susan J. Little, Sanjay R. Mehta, Travis Sanchez, Jeremy Sugarman, John Fp Bridges

    Background: Molecular HIV surveillance (MHS) is used in the U.S. to inform public health prevention and intervention activities aimed at helping end the HIV epidemic. Its application in this context is currently challenged by ethical, legal, and social concerns, with gaps in understanding how end users weigh these issues. We sought to identify the preferences of MHS end users for improving MHS. Methods: End users completed 12 choice experiment tasks evaluating five attributes of MHS for cluster detection and response. We generated a choice model using conditional logit and report results as relative attribute importance scores, comparing them to attitudinal data from close-ended questions. Responses to open-ended questions provide additional context on areas for MHS improvement. Results: We report findings from 55 of 90 potential end-users who felt capable and agreed to participate. End users include researchers (n = 28) and public health practitioners (n = 27); their preferences do not differ significantly (p = 0.174) so their responses are combined. The highest weight is placed on certainty of MHS benefit (38%), followed by depth of HIV sequence sampling (26%). Lower weight is given to reducing stigma (20%) and personalized inferences (10%) and communication (6%). End users highlight improving MHS through implementation support, community engagement, transparent communication, intervention assistance, risk minimization, and impact assessment; researchers stress the need for better data access. Conclusions: End users place the highest value on having more evidence of MHS benefits. Improving MHS requires attention to implementation support, community engagement, transparent communication, intervention assistance, risk mitigation, impact assessment, and data access.


  • Top Cited Papers

    Patient-reported outcome measures add value as clinical trial endpoints

    by Norah L. Crossnohere, Anne L. R. Schuster, Jeffrey Bruckel, Ronald C. Chen, Amy M. Cizik, Samantha Cruz Rivera, Christopher Muth, Linda Nelsen, Derek Kyte, Albert W. Wu, et al.


  • Open Access

    Optimizing participant and community engagement in cancer genomic sequencing research

    by Norah L Crossnohere, Anne L R Schuster, Cindy K Blair, Hasani Bland, John D Carpten, Elizabeth B Claus, Graham A Colditz, Diane Diehl, Li Ding, Bettina F Drake, et al.


  • Open Access

    User experience with HIV molecular epidemiology in research, surveillance, and cluster detection and response: a needs assessment

    by Anne L.R. Schuster, Ashley Folta, Juli Bollinger, Gail Geller, Sanjay R. Mehta, Susan J. Little, Travis Sanchez, Jeremy Sugarman, John F.P. Bridges

    HIV molecular epidemiology (HIV ME) is a tool that aims to improve HIV research, surveillance, and cluster detection and response. HIV ME is a core pillar of the U.S. initiative to End the HIV Epidemic but faces some challenges and criticisms from stakeholders. We sought to assess user experience to identify the current needs for HIV ME. Users of HIV ME, including researchers and public health practitioners, were engaged via a structured survey. Needs were assessed via open-ended questions about HIV ME. Data were analyzed using reflexive thematic analysis; the concordance of results was assessed semi-quantitatively. Of 90 possible HIV-ME end-users, 57 completed the survey (response rate = 63%), which included users engaged in research (n = 29) and public health (n = 28). Respondents identified current imperatives, challenges, and strategies to improve HIV ME. Imperatives included characterization of the virus, identification of HIV hotspots, and tailoring of HIV interventions. Challenges encompassed technological issues, ethical concerns, and implementation difficulties. Strategies to improve HIV ME involved improving data access and analysis, enhancing implementation guidance and resources, and fostering community engagement and support. Researchers and public health practitioners prioritized different imperatives, but similarly emphasized the ethical concerns with HIV ME. The imperatives identified by users underscore the necessity of HIV ME, while the challenges highlight the hurdles to be overcome, including ethical concerns which emerged as a shared emphasis across user groups. The strategies outlined offer a roadmap for overcoming these challenges. These insights, drawn from user experience, present a valuable opportunity to inform the development of guidelines for the ethical application of HIV ME in research, surveillance, and cluster detection and response.


  • A Framework to Promote Implementation of Patient-Reported Outcomes in Institutions Caring for Vulnerable and Underserved Cancer Populations

    by Anne L. R. Schuster, Norah L. Crossnohere, Eric Adjei Boakye, Rebekah Angove, Billie Baldwin, Esteban A. Barreto, Ronald C. Chen, Theresa W. Gillespie, Betty Hamilton, Nadine Jackson McCleary, et al.


  • Open Access

    Prioritization of ethical concerns regarding HIV molecular epidemiology by public health practitioners and researchers

    by Anne L. R. Schuster, Juli Bollinger, Gail Geller, Susan J. Little, Sanjay R. Mehta, Travis Sanchez, Jeremy Sugarman, John F. P. Bridges

    Background: HIV molecular epidemiology (HIV ME) can support the early detection of emerging clusters of new HIV infections by combining HIV sequence data routinely obtained during the clinical treatment of people living with HIV with behavioral, geographic, and sociodemographic information. While information about emerging clusters promises to facilitate HIV prevention and treatment efforts, the use of this data also raises several ethical concerns. We sought to assess how those working on the frontlines of HIV ME, specifically public health practitioners (PHPs) and researchers, prioritized these issues. Methods: Ethical issues were identified through literature review, qualitative in-depth interviews, and stakeholder engagement. PHPs and researchers using HIV ME prioritized the issues using best–worst scaling (BWS). A balanced incomplete block design was used to generate 11 choice tasks each consisting of a sub-set of 5 ethical concerns. In each task, respondents were asked to assess the most and least concerning issue. Data were analyzed using conditional logit, with a Swait-Louviere test of poolability. Latent class analysis was then used to explore preference heterogeneity. Results: In total, 57 respondents completed the BWS experiment May–June 2023 with the Swait-Louviere test indicating that researchers and PHPs could be pooled (p = 0.512). Latent class analysis identified two classes, those highlighting “Harms” (n = 29) (prioritizing concerns about potential risk of legal prosecution, individual harm, and group stigma) and those highlighting “Utility” (n = 28) (prioritizing concerns about limited evidence, resource allocation, non-disclosure of data use for HIV ME, and the potential to infer the directionality of HIV transmission). There were no differences in the characteristics of members across classes. Conclusions: The ethical issues of HIV ME vary in importance among stakeholders, reflecting different perspectives on the potential impact and usefulness of the data. Knowing these differences exist can directly inform the focus of future deliberations about the policies and practices of HIV ME in the United States.


  • Open Access

    Data from Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network

    by Anne Lr. Schuster, Norah L. Crossnohere, Melinda Bachini, Cindy K. Blair, John D. Carpten, Elizabeth B. Claus, Graham A. Colditz, Li Ding, Bettina F. Drake, Ryan C. Fields, et al.

    Background:Engaging diverse populations in cancer genomics research is of critical importance and is a fundamental goal of the NCI Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Established as part of the Cancer Moonshot, PE-CGS is a consortium of stakeholders including clinicians, scientists, genetic counselors, and representatives of potential study participants and their communities. Participant engagement is an ongoing, bidirectional, and mutually beneficial interaction between study participants and researchers. PE-CGS sought to set priorities in participant engagement for conducting the network's research.Methods:PE-CGS deliberatively engaged its stakeholders in the following four-phase process to set the network's research priorities in participant engagement: (i) a brainstorming exercise to elicit potential priorities; (ii) a 2-day virtual meeting to discuss priorities; (iii) recommendations from the PE-CGS External Advisory Panel to refine priorities; and (iv) a virtual meeting to set priorities.Results:Nearly 150 PE-CGS stakeholders engaged in the process. Five priorities were set: (i) tailor education and communication materials for participants throughout the research process; (ii) identify measures of participant engagement; (iii) identify optimal participant engagement strategies; (iv) understand cancer disparities in the context of cancer genomics research; and (v) personalize the return of genomics findings to participants.Conclusions:PE-CGS is pursuing these priorities to meaningfully engage diverse and underrepresented patients with cancer and posttreatment cancer survivors as participants in cancer genomics research and, subsequently, generate new discoveries.Impact:Data from PE-CGS will be shared with the broader scientific community in a manner consistent with participant informed consent and community agreement.

  • Open Access

    Data from Priorities to Promote Participant Engagement in the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network

    by Anne Lr. Schuster, Norah L. Crossnohere, Melinda Bachini, Cindy K. Blair, John D. Carpten, Elizabeth B. Claus, Graham A. Colditz, Li Ding, Bettina F. Drake, Ryan C. Fields, et al.

    Background:Engaging diverse populations in cancer genomics research is of critical importance and is a fundamental goal of the NCI Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. Established as part of the Cancer Moonshot, PE-CGS is a consortium of stakeholders including clinicians, scientists, genetic counselors, and representatives of potential study participants and their communities. Participant engagement is an ongoing, bidirectional, and mutually beneficial interaction between study participants and researchers. PE-CGS sought to set priorities in participant engagement for conducting the network's research.Methods:PE-CGS deliberatively engaged its stakeholders in the following four-phase process to set the network's research priorities in participant engagement: (i) a brainstorming exercise to elicit potential priorities; (ii) a 2-day virtual meeting to discuss priorities; (iii) recommendations from the PE-CGS External Advisory Panel to refine priorities; and (iv) a virtual meeting to set priorities.Results:Nearly 150 PE-CGS stakeholders engaged in the process. Five priorities were set: (i) tailor education and communication materials for participants throughout the research process; (ii) identify measures of participant engagement; (iii) identify optimal participant engagement strategies; (iv) understand cancer disparities in the context of cancer genomics research; and (v) personalize the return of genomics findings to participants.Conclusions:PE-CGS is pursuing these priorities to meaningfully engage diverse and underrepresented patients with cancer and posttreatment cancer survivors as participants in cancer genomics research and, subsequently, generate new discoveries.Impact:Data from PE-CGS will be shared with the broader scientific community in a manner consistent with participant informed consent and community agreement.